je.st
news
Amgen Announces Top-Line Secondary Endpoint Results Of Phase 3...
2014-11-05 13:20:10| Biotech - Topix.net
Amgen today announced the top-line secondary endpoint results of overall survival from the Phase 3 TRINOVA-1 trial in women with recurrent platinum-resistant ovarian cancer. The study, which evaluated trebananib plus paclitaxel versus placebo plus paclitaxel, did not demonstrate a statistically significant improvement in overall survival.
Tags: results
phase
secondary
announces
Category:Biotechnology and Pharmaceuticals
Latest from this category |
All news |
||||||||||||||||||||
|
|
||||||||||||||||||||